DUBLIN–(BUSINESS WIRE)–The “Thymidylate synthase inhibitors – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Thymidylate synthase inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Thymidylate synthase inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Thymidylate synthase inhibitors: Overview
Thymidylate synthase is an important enzyme, which is responsible for the reductive methylation of deoxyuridylic acid (dUMP) to deoxythymidylic acid (dTMP). The methylation of the uracil moiety (present in RNA) to 5-methyl uracil (thymine, present in DNA) requires participation of a folic acid coenzyme, N5, N10-methylenetetrahydrofolate as a methyl donor.
Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme thymidylate synthase and have potential as an anticancer chemotherapy.[1] This inhibition prevents the methylation of C5 of deoxyuridine monophosphate (dUMP) thereby inhibiting the synthesis of deoxythymidine monophosphate (dTMP).
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Thymidylate synthase inhibitors R&D. The therapies under development are focused on novel approaches for Thymidylate synthase inhibitors.
Thymidylate synthase inhibitors Emerging Drugs Chapters
This segment of the Thymidylate synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thymidylate synthase inhibitors Emerging Drugs
ADX 2191: Aldeyra Therapeutics
ADX-2191, an intravitreal formulation of methotrexate, has been granted orphan drug designation for the prevention of proliferative vitreoretinopathy (PVR). The observed clinical activity of ADX-2191 in patients with PVR is believed to be the result of down-regulation of aberrant retinal cell proliferation and activity, thereby leading to reduced retinal scarring that is characteristic of PVR. Aldeyra retains an exclusive license to certain patents related to the use of ADX-2191 for the prevention of PVR.
LY-01616: Luye Pharma
LY01616 is an innovative combinational liposome formulation loaded with irinotecan and floxurudine, indicated for the treatment of advanced colorectal cancer. LY01616 was independently developed by Luye Pharma through its Laboratory for Long-acting and Targeting Drug Delivery Systems.
Thymidylate synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Thymidylate synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Thymidylate synthase inhibitors
There are approx. 18+ key companies which are developing the Thymidylate synthase inhibitors. The companies which have their Thymidylate synthase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Aldeyra Therapeutics.
Key Players
- Aldeyra Therapeutics
- Luye Pharma Group
- Nucana BioMed
- Roche
- ROS Therapeutics
- Nordic Group
- Taiho Pharmaceutical
- Fivephusion
- Isofol Medical
- Eli Lilly and Company
- Nucana BioMed
- Mebiopharm
- Atlanthera
- SetLance
- Cardiol Therapeutics
- Venus Remedies
- Lumosa Therapeutics
- Celator Pharmaceuticals
- Sanofi
Key Products
- ADX 2191
- LY01616
- Fosifloxuridine nafalbenamide
- Capecitabine
- SAR-439281
- NUC 3373
- MBP Y003
- CTX02
- VRT 002 P
- CPX-1
- LT 2003
- Research programme – neurotensin conjugated anticancer therapies
- 1102-39
- Methotrexate prodrug
- Nordimet
- Pemetrexed
- SP-05
- TS-1
- LV/5-FU
Key Topics Covered:
Introduction
Executive Summary
Thymidylate synthase inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Thymidylate synthase inhibitors – Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
ADX 2191: Aldeyra Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
SAR-439281: Sanofi
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Fosifloxuridine nafalbenamide: Nucana BioMed
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Methotrexate prodrug: ROS Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Thymidylate synthase inhibitors Key Companies
Thymidylate synthase inhibitors Key Products
Thymidylate synthase inhibitors- Unmet Needs
Thymidylate synthase inhibitors- Market Drivers and Barriers
Thymidylate synthase inhibitors- Future Perspectives and Conclusion
Thymidylate synthase inhibitors Analyst Views
Thymidylate synthase inhibitors Key Companies
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/zhmmf3
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900